211 related articles for article (PubMed ID: 32290440)
41. Changes in the Expression of Pre-Replicative Complex Genes in hTERT and ALT Pediatric Brain Tumors.
Idilli AI; Pagani F; Kerschbamer E; Berardinelli F; Bernabé M; Cayuela ML; Piazza S; Poliani PL; Cusanelli E; Mione MC
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331249
[No Abstract] [Full Text] [Related]
42. Telomere Transcripts Target Telomerase in Human Cancer Cells.
Kreilmeier T; Mejri D; Hauck M; Kleiter M; Holzmann K
Genes (Basel); 2016 Aug; 7(8):. PubMed ID: 27537914
[TBL] [Abstract][Full Text] [Related]
43. Telomere maintenance in sarcomas.
Johnson JE; Broccoli D
Curr Opin Oncol; 2007 Jul; 19(4):377-82. PubMed ID: 17545803
[TBL] [Abstract][Full Text] [Related]
44. Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences.
Yu Y; Katiyar SP; Sundar D; Kaul Z; Miyako E; Zhang Z; Kaul SC; Reddel RR; Wadhwa R
Cell Death Dis; 2017 Apr; 8(4):e2755. PubMed ID: 28425984
[TBL] [Abstract][Full Text] [Related]
45. Multiple mechanisms of telomere maintenance exist in liposarcomas.
Johnson JE; Varkonyi RJ; Schwalm J; Cragle R; Klein-Szanto A; Patchefsky A; Cukierman E; von Mehren M; Broccoli D
Clin Cancer Res; 2005 Aug; 11(15):5347-55. PubMed ID: 16061847
[TBL] [Abstract][Full Text] [Related]
46. Alternative Lengthening of Telomeres Mediated by Mitotic DNA Synthesis Engages Break-Induced Replication Processes.
Min J; Wright WE; Shay JW
Mol Cell Biol; 2017 Oct; 37(20):. PubMed ID: 28760773
[TBL] [Abstract][Full Text] [Related]
47. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT.
Cerone MA; Autexier C; Londoño-Vallejo JA; Bacchetti S
Oncogene; 2005 Nov; 24(53):7893-901. PubMed ID: 16116482
[TBL] [Abstract][Full Text] [Related]
48. Alternative lengthening of telomeres in human cells.
Reddel RR; Bryan TM; Colgin LM; Perrem KT; Yeager TR
Radiat Res; 2001 Jan; 155(1 Pt 2):194-200. PubMed ID: 11121234
[TBL] [Abstract][Full Text] [Related]
49. Telomeres as targets for anticancer therapies.
Folini M; Venturini L; Cimino-Reale G; Zaffaroni N
Expert Opin Ther Targets; 2011 May; 15(5):579-93. PubMed ID: 21288186
[TBL] [Abstract][Full Text] [Related]
50. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
51. [Suppression of alternative telomere lengthening in cancer cells with reverse transcriptase inhibitors].
Bondarev IE; Khavinson VK
Adv Gerontol; 2016; 29(2):218-221. PubMed ID: 28514537
[TBL] [Abstract][Full Text] [Related]
52. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.
Ulaner GA; Huang HY; Otero J; Zhao Z; Ben-Porat L; Satagopan JM; Gorlick R; Meyers P; Healey JH; Huvos AG; Hoffman AR; Ladanyi M
Cancer Res; 2003 Apr; 63(8):1759-63. PubMed ID: 12702558
[TBL] [Abstract][Full Text] [Related]
53. A novel telomere structure in a human alternative lengthening of telomeres cell line.
Marciniak RA; Cavazos D; Montellano R; Chen Q; Guarente L; Johnson FB
Cancer Res; 2005 Apr; 65(7):2730-7. PubMed ID: 15805272
[TBL] [Abstract][Full Text] [Related]
54. Targeting the telosome: therapeutic implications.
Folini M; Gandellini P; Zaffaroni N
Biochim Biophys Acta; 2009 Apr; 1792(4):309-16. PubMed ID: 19419699
[TBL] [Abstract][Full Text] [Related]
55. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
56. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
57. [The role of telomere-binding proteins in carcinogenesis].
Aragona M; Pontoriero A; Panetta S; La Torre I; La Torre F
Minerva Med; 2000; 91(11-12):299-304. PubMed ID: 11253711
[TBL] [Abstract][Full Text] [Related]
58. Alternative lengthening of telomeres in mammalian cells.
Henson JD; Neumann AA; Yeager TR; Reddel RR
Oncogene; 2002 Jan; 21(4):598-610. PubMed ID: 11850785
[TBL] [Abstract][Full Text] [Related]
59. [The role of alternative lengthening of telomeres mechanisms in carcinogenesis and prospects for using an anti-telomerase drugs in malignant tumors treatment].
Grach AA
Tsitologiia; 2011; 53(10):759-71. PubMed ID: 22232932
[TBL] [Abstract][Full Text] [Related]
60. Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition.
Deeg KI; Chung I; Bauer C; Rippe K
Front Oncol; 2016; 6():186. PubMed ID: 27602331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
